Which allergy medication generated almost $100M in its first 16 weeks on the shelf?

In its first 16 weeks on the shelf, GlaxoSmithKline's new allergy remedy Flonase brought in almost $100 million and jumped to the top of category according to IRI figures, reported Drug Store News.

Early last month, GlaxoSmithKline's CFO told analyists that the $100 million, "accounted for half of the division's 24% growth in quarterly sales," according to the article.

Coming in second on the list was Nasacort Allergy 24HR, which brought in just over $40 million.